GlobeNewswire

Zinpro Corporation Announces Executive Leadership Changes

Dela

Anderson Promotes Scrimgeour to President & CEO, and Sheffer Joins Company as COO

EDEN PRAIRIE, Minn., June 13, 2017 (GLOBE NEWSWIRE) -- Zinpro Corporation announces that its owner, Michael D. Anderson, has promoted William Scrimgeour to be the company's next president and CEO. The transfer in CEO responsibilities to Scrimgeour will allow Anderson to concentrate more time and energy on his role as chairman of the board of directors. Anderson has held his positions as CEO and board of directors chairman for Zinpro Corporation since May, 1992.

The change in responsibilities will enable Anderson to more effectively lead the board of directors to set the company's future course and to provide strategic direction as the company continues to expand globally. "In the next five years, we anticipate our company's growth to increase rapidly worldwide, and we need to not only enhance our efforts in areas that will count most, but also add to our leadership team as we prepare for the future," says Anderson. "Handing off my CEO responsibilities will also allow me to concentrate more on how to expand the scope of our company's positive global impact, both on animals and people."

Anderson's successful tenure as CEO is marked by many accomplishments since taking on the role from his father and founder, Dean Anderson. Over the past 25 years, Michael Anderson has led the company to develop and launch more than 75 new products, to expand sales into 60 additional countries, to build three manufacturing facilities and to establish nine international subsidiaries and two new business ventures. In addition, he has guided the expansion of Zinpro Corporation into a leading global exporter of Performance Minerals®.

Scrimgeour takes on his new position as president and CEO, having previously served Zinpro Corporation as president and Chief Operating Officer (COO) since 2008. "Over the last nine years, Bill has excelled in overseeing all company departments and managing day-to-day operations," says Anderson. "I'm confident Bill will be instrumental in helping Zinpro to continue to meet the demand from an ever-increasing global customer base who desires our products and services to improve animal wellness and performance."

With Scrimgeour taking on the position of CEO, the company also announces that Rob Sheffer has joined Zinpro Corporation as its new COO. Sheffer comes to Zinpro with more than 25 years of leadership experience - most of it with a global animal nutrition company. Sheffer's wide-ranging leadership experience includes positions as president and CEO, group director, managing director, regional sales leader and branch manager. He also served as board chair for the American Feed Industry Association from 2015-2016.

"Rob has a proven track record for developing, motivating and inspiring teams to achieve business growth, including growth in global markets," says Scrimgeour. "I'm very pleased to welcome him to Zinpro to be our next COO. His extensive leadership experience in the feed and animal nutrition industries will serve him well, and Zinpro well, as our company continues to expand worldwide."

As the industry leader in trace mineral nutrition for livestock and poultry, Zinpro is committed to delivering the technical expertise, products and educational tools needed to help customers improve the performance and profitability of their operations.

About Zinpro Corporation

More than 45 years ago, Zinpro Corporation pioneered the research and development of Performance Minerals®. As a family-owned, privately-held company, Zinpro Corporation's steady growth has come as a result of quality products, quality people and a focus on one thing: performance trace minerals for exceptional animal nutrition. Today, the company has regional sales offices located in nine countries and markets its products in more than 70 countries worldwide. For more information, visit zinpro.com, or call +1 952-983-4000.

Performance Minerals® is a registered trademark of Zinpro Corporation. ©2017 Zinpro Corp. All rights reserved.

For more information, contact:
John Pocock
Corporate Communications Specialist
Zinpro Corporation
+1 952-983-3937
jpocock@zinpro.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zinpro Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum